Upgrade to SI Premium - Free Trial

Morgan Stanley Downgrades Acadia Pharmaceuticals (ACAD) to Equalweight

August 7, 2024 3:35 AM
Morgan Stanley analyst Jeffrey Hung downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Overweight to Equalweight with a price target of $20.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Downgrades

Next Articles